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The peritoneal equilibration test (PET) with 3.86% glucose
concentration (3.86%-PET) has been suggested to be more
useful than the standard 2.27%-PET in peritoneal dialysis
(PD), but no longitudinal data for 3.86%-PET are currently
available. A total of 242 3.86%-PETs were performed in 95
incident PD patients, who underwent the first test during the
first year of treatment and then once a year. The classical
parameters of peritoneal transport, such as peritoneal
ultrafiltration (UF), D/D0, and D/PCreat, were analyzed. In
addition, the absolute dip of dialysate sodium concentration
(DDNa), as an expression of sodium sieving, was studied. D/D0
was stable, and a progressive decrease in UF was observed
after the second PET, whereas D/PCreat firstly increased and
then stabilized. DDNa was the only parameter showing a
progressive decrease over time. On univariate analysis, D/D0
and DDNa were found to be significantly associated with the
risk of developing UF failure (risk ratio (RR) 0.987
(0.973–0.999), P¼ 0.04, and RR 0.768 (0.624–0.933), P¼ 0.007,
respectively), but on multivariate analysis only DDNa showed
an independent association with the risk of developing UF
failure (RR 0.797 (0.649–0.965), P¼ 0.020). UF, D/D0, and
D/PCreat changed only in those patients developing UF failure,
reflecting increased membrane permeability, whereas DDNa
significantly decreased in all patients. The 3.86%-PET allows a
more complete study of peritoneal membrane transport than
the standard 2.27%-PET. DDNa shows a constant and
significant reduction over time and is the only factor
independently predicting the risk of developing UF failure
in PD patients.
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The peritoneal equilibration test (PET) was introduced into
clinical practice by Twardowski et al.1 to investigate the
transport characteristics of the peritoneal membrane and to
give data to tailor the dialysis prescription in patients on
peritoneal dialysis (PD). The original method is performed
using a single peritoneal dwell 4-h long and a solution with
a glucose concentration of 2.27% (2.27%-PET). During the
test, the plasma and dialysate creatinine concentrations and
the dialysate glucose concentration at the start and at the end
of the test are assessed; peritoneal ultrafiltration (UF) is also
measured. According to the transport characteristics
with respect to the dialysate-to-plasma ratio of creatinine
(D/PCreat) and the dialysate glucose concentration at the
end of the test compared to the start (D/D0), PD patients
are categorized as low (L), low-average (L-A), high-average
(H-A), and high (H) transporters. UF capacity is also
classified by the same method.1
Peritoneal UF failure is an important cause of reduced
patient and technique survival in PD patients.2–4 The PET
with 3.86% glucose dialysate concentration (3.86%-PET)
could be more useful than the standard 2.27%-PET to
evaluate peritoneal UF in PD patients,5 as the larger drained
volume reduces the likelihood of measurement errors. In
addition, the 3.86%-PET is capable of giving an estimate of
aquaporin-1-mediated water transport;6,7 the reduction in
dialysate sodium concentration usually observed during a
hypertonic dwell, a phenomenon called sodium sieving (SNa),
is explained by transcellular free-water moving through
endothelial channels impermeable to solutes (aquaporin-1),
which therefore causes dilution of the dialysate over the first
2 h of the dwell.8–10 At the same time, a number of studies
have shown that the glucose concentration does not influence
the peritoneal transport of small solutes and the related
indexes, such as D/PCreat,
11–13 and reference values for solute
and fluid transport using a modified 3.86%-PET have been
recently evaluated in a large group of prevalent PD patients.14
However, unlike the standard 2.27%-PET, for which time
changes of peritoneal UF and small solutes transport
characteristics are available,15–19 no longitudinal data have
so far been collected with the 3.86%-PET.
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 14 September 2005; revised 28 October 2005; accepted 28
October 2005; published online 18 January 2006
Correspondence: V La Milia, Department of Nephrology and Dialysis,
A. Manzoni Hospital, Via dell’Eremo 9/11, 23900 Lecco, Italy.
E-mail:v.lamilia@ospedale.lecco.it
Kidney International (2006) 69, 927–933 927
This study was aimed at evaluating the variations over
time of the peritoneal transport of small solutes, of SNa and of
UF in a cohort of incident PD patients, using the 3.86%-PET.
RESULTS
Ninety-five patients (M/F 45/50), who underwent at least one
3.86%-PET within 12 months from the start of PD, were
examined and followed up for a median of 25 months (total
range 4–153 months) (Figure 1). A total of 242 3.86%-PETs
were performed, without any complications (except only one
patient experiencing cramps). Primary diagnoses of renal
failure were glomerulonephritis 33 (34.7%), hypertensive
nephropathy 14 (14.7%), adult polycystic renal disease 12
(12.6%), reflux nephropathy/interstitial nephritis 14 (14.7%),
diabetic nephropathy 11 (11.6%), and small kidneys/
unknown 11 (11.6%). At the start of PD, patients had a
median age of 61 years (total range 27–83 years); the median
duration of PD at the time of the first PET was 3.6 months
(inter-quartile range 2.9–5.0 months). Baseline peritoneal
transport characteristics, obtained during the first 3.86%-
PET, were as follows: UF 7377228 ml, D/D0 0.2370.06,
D/PCreat 0.7170.09, DDNa 9.773.0 mmol/l. According to
these baseline values, patients were categorized into four
transporter groups (Table 1). A number of baseline factors
significantly correlated, albeit weakly, with UF. On multi-
variate analysis, gender, age at start of PD therapy, urine
volume, D/PCreat, and DDNa remained significant indepen-
dent covariates, accounting for 25% of the variability
(Table 2). In 13 patients with two repeated (after 48 h)
3.86%-PETs, the pooled coefficient of variation for the net
UF volume was found to be 7.8%.
Patients were then evaluated according to the minimal
number of PETs performed, and independently analyzed as
different cohorts, as described above (Figure 2). In 62
patients, at least two PETs were performed; in these patients,
UF and D/D0 remained stable, D/PCreat increased and DDNa
decreased between the first and the second PET. In 42
patients in whom at least three PETs were performed, UF
showed a significant reduction at the third PET, D/D0 was
substantially stable, D/PCreat increased at the second PET but
showed a reduction at the third PET with a general trend that
was not statistically significant, and DDNa significantly
decreased over time. In 20 patients in whom at least four
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Figure 1 | Flow chart of patients during the study. ‘Still on PD’ patients indicate those who were still on PD therapy at the end of the
follow-up. Data are expressed as means7s.d. or as median with inter-quartile range within brackets.
Table 1 | Number of patients assigned to different transpor-
ters categories, as assessed by baseline D/PCreat, D/D0, and UF
values (n=95)
D/PCreat (%) D/D0 (%)
a UF (%)
High 17 (17.9) 16 (17.0) 12 (12.6)
High-average 33 (34.7) 35 (37.2) 38 (40.0)
Low-average 33 (34.7) 27 (28.7) 28 (29.5)
Low 12 (12.6) 16 (17.0) 17 (17.9)
D/PCreat, dialysate-to-plasma ratio of creatinine concentration at the end of the PET;
D/D0, ratio of dialysate glucose concentration at the end and at the start of the PET;
UF, peritoneal ultrafiltration.
an=94.
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PETs were performed, UF showed a significant reduction at
the third PET, D/D0 and D/PCreat remained stable, and DDNa
significantly decreased over all the PETs. Finally, in 11
patients in whom at least five PETs were performed, the only
variable that showed a significant variation over time was
DDNa, which halved in 5 years; also UF progressively
decreased, but the reduction was not statistically significant.
When analyzing the mean differences of peritoneal
transport characteristics between the last and the first PET
in all patients with at least two PETs performed, UF and
DDNa were the only parameters showing a significant
reduction (Table 3). The reduction of UF and DDNa were
–3.0710.2 ml/month of PD therapy and 0.0970.12 mmol/
l/month of PD therapy, respectively.
A number of factors correlated, albeit weakly, with UF
decrease over time. However, on multivariate analysis,
excluding baseline UF because of autocorrelation, no factor
was predictive of UF decrease (data not shown).
During the study, 15 out of 95 patients developed
peritoneal UF failure, as defined above (two patients at the
first, three patients at the second, four patients at the third,
three patients at the fourth, and three patients at the fifth
PET). The proportion of patients without UF failure was
98% (95% confidence intervals: 94–100%) at 1 year, 92%
(95% confidence intervals: 85–99%) at 2 years, and 84%
(95% confidence intervals: 73–95%) at 3 years (Figure 3).
With the Cox univariate regression model, only D/D0 and
DDNa were found to be significantly associated with the risk
of developing UF failure (risk ratio (RR) 0.987 (0.973–0.999),
P¼ 0.04, and RR 0.768 (0.624–0.933), P¼ 0.007, respectively)
(Table 4). However, on Cox multivariate analysis, only DDNa
remained significantly associated with the risk of developing
UF failure (RR 0.797 (0.649–0.965), P¼ 0.020).
No differences were observed between patients with and
without UF failure as to baseline characteristics (Table 5),
whereas the number of peritonitis and the number of patients
with at least one episode of peritonitis during the follow-up
were higher in the group with UF failure, although not
significantly (0 (0–1) vs 1 (0–2), P¼ 0.250, and 9 (69%) vs 21
(45%), P¼ 0.209, respectively).
Peritoneal UF and membrane transport characteristics (D/
D0 and D/PCreat) remained stable in the group without UF
failure, whereas patients developing UF failure showed a
reduction of UF and an increase of membrane permeability
(as indicated by increased D/PCreat and decreased D/D0);
however, DDNa significantly decreased in both groups
(Figure 4).
Table 2 | Multivariate regression of baseline factors
associated with baseline UF
Standardized
b coefficient t P-value
Model constant 5.06 o0.001
Sex (female) 47.4 2.1 0.043
Age at start of PD (1 year) 3.3 2.1 0.036
Urine volume (1 ml) 0.07 2.4 0.018
D/PCreat (0.001) 0.60 2.28 0.025
DDNa (1 mmol/l) 17.3 2.25 0.027
DDNa, absolute dip of sodium dialysate sodium concentration at 60 min. See Table 1
for other abbreviations.
ANOVA for model Po0.001, R2=0.25.
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Figure 2 | Changes of peritoneal transport characteristics in
patients with at least two 3.86%-PETs (two PETs) (n¼ 62), at least
three 3.86%-PETs (three PETs) (n¼ 42), at least four 3.86%-PETs
(four PETs) (n¼ 20), and at least five 3.86%-PETs (five PETs)
(n¼ 11). UF: two PETs P¼ 0.671; three PETs P¼ 0.014; four PETs
P¼ 0.012; five PETs P¼ 0.114. D/D0: two PETs P¼ 0.464; three PETs
P¼ 0.705; four PETs P¼ 0.589; five PETs P¼ 0.057. D/PCreat: two PETs
P¼ 0.043; three PETs P¼ 0.142; four PETs P¼ 0.241; five PETs
P¼ 0.398. DDNa: two PETs Po0.001; three PETs Po0.001; four PETs
Po0.001; five PETs P¼ 0.048. Data are expressed as means7s.e.
See Tables 1 and 2 for abbreviations.
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Figure 3 | Kaplan–Meier curve of proportion of patients with and
without UF failure during the follow-up (n¼ 95).
Table 3 | Mean differences in peritoneal transport character-
istics between the last and the first PET in patients who
performed at least two 3.86%-PETs (n=62)
Mean difference P
UF (ml) 1267334 0.004
D/D0 0.00 (0.04–0.04) 0.601
D/PCreat 0.0270.11 0.127
DDNa (mmol/l) 3.174.0 o0.001
Data are expressed as means7s.d. or as median with inter-quartile range within
brackets.
See Tables 1 and 2 for abbreviations.
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The correlations of the differences between the first and
the last PET plotted against the average of the initial and final
values were small for all the examined parameters (UF:
r¼ 0.19; D/D0: r¼ 0.31; D/PCreat: r¼ 0.24; DDNa: r¼ 0.23),
suggesting a small influence of the phenomenon of regression
to the mean.
DISCUSSION
The 2.27%-PET has become the standard of care for PD
prescription. More recently, the 3.86%-PET has been
introduced to provide better information on UF, because
the larger drained volume reduces the likelihood of
measurement errors, and on free-water transport by means
of SNa. Indeed, the coefficient of variation of UF was only
7.8% in a subgroup of patients of our study, whereas it has
been reported as being closer to 50% with the use of 2.27%-
PET.19 UF, its variations, and its relationship with other
parameters of solute transport through the peritoneal
membrane are therefore better assessed with the use of the
3.86%-PET. Furthermore, the 3.86%-PET is also capable of
giving an estimate of aquaporin-1-mediated free-water
transport.
In our knowledge, this study represents the first
prospective evaluation of peritoneal transport properties
assessed by 3.86%-PET in a large group of incident PD
patients. Its findings could be of particular relevance when
considering the advice of the ISPD committee on UF failure,
who recommended the use of the 3.86%-PET in everyday
clinical practice instead of the 2.27%-PET.5 Indeed, reference
values for parameters of peritoneal solute transport obtained
with this method are still lacking in incident PD patients. In
this study, we provided the baseline characteristics of
peritoneal solute transport of all incident patients with at
least one 3.86%-PET performed within 12 months from the
start of PD. In general, we found higher transport of low
molecular weight solutes compared to those obtained in
a similar study by Smit et al.14 In particular, in our study,
D/PCreat and UF were higher and D/D0 was lower than those
found in that recent study.14 These differences could be
explained by the fact that Smit et al.14 calculated their
reference values in patients who had been on PD therapy over
a wide range of time (3 months–12 years) after excluding
patients with UF failure (approach A), or analyzing all
patients within their first 2 years of PD therapy without the
exclusion of patients with UF failure (approach B). Our
baseline data are more homogenous, given that the first PET
was always performed in the first year from the start of
treatment.
We also prospectively examined peritoneal SNa, as DDNa at
60 min of the test, peritoneal transport of low molecular
solutes and UF in all PD patients with more than one 3.86%-
PET performed. The analyses were performed separately in
the different cohorts obtained by dividing the patients
according to the minimal number of PETs performed,
because the systematic loss of patients occurring throughout
the follow-up could have distorted the real mean values of the
single parameters. For this reason, we decided to compare the
baseline properties of peritoneal solute transport at the first
PET with those at subsequent PETs in the same cohort of
patients. An interesting finding of this study is that UF and
Table 4 | Cox univariate regression model for the develop-
ment of UF failure during the follow-up in 95 patients on PD
therapy
Risk
ratio
Lower
CI
Upper
CI P
Sex (female) 0.754 0.438 1.336 0.369
Age at start of PD (increase of 1 year) 1.010 0.970 1.053 0.618
Urine volume (increase of 1 ml) 0.999 0.999 1.000 0.995
GFR (increase of 1 ml/min) 0.906 0.696 1.134 0.406
Plasma Albumin (increase of 1 g/dl) 0.464 0.114 1.742 0.259
UF (increase of 1 ml) 0.998 0.997 1.000 0.225
D/D0 (increase of 0.001) 0.987 0.973 0.999 0.043
D/PCreat (increase of 0.001) 1.005 0.998 1.012 0.161
DDNa (increase of 1 mmol/l) 0.768 0.624 0.933 0.008
GFR, glomerular filtration rate; CI, confidence interval; see Tables 1 and 2 for other
abbreviations.
Table 5 | Baseline characteristics of patients without and with
UF failure who performed at least two 3.86%-PETs (n=60)
UF Normal UFF P
Age (years) 58712 55718 0.504
M/F 23/24 5/8 0.500
Plasma Albumin (g/dl) 3.8770.39 3.8470.42 0.853
Urine volume (ml) 1000 (600–1400) 520 (235–1295) 0.202
GFR (ml/min) 2.6 (1.5–4.4) 1.6 (0.4–3.2) 0.148
UF (ml) 7447243 7717109 0.697
D/D0 0.2370.05 0.2170.04 0.346
D/PCreat 0.7270.09 0.7370.05 0.603
DDNa (mmol/l) 10.073.4 8.473.0 0.103
GFR, glomerular filtration rate; see Tables 1 and 2 for other abbreviations.
Data are expressed as means7s.d. or as median with inter-quartile range within
parentheses.
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Figure 4 | Changes of peritoneal transport characteristics be-
tween the first and the last PET in patients with (UFF) and
without (UFN) UF failure (n¼ 60). Data are shown as means7
standard error *P¼ 0.575 vs first PET; *Po0.001 vs UFF; **Po0.001 vs
first PET. yP¼ 0.883 vs first PET; yP¼ 0.014 vs UFF; yyP¼ 0.031 vs first
PET. 1P¼ 0.736 vs first PET; 1P¼ 0.046 vs UFF; 11P¼ 0.014 vs first PET.
#Po0.001 vs first PET; #P¼ 0.005 vs UFF; ##P¼ 0.006 vs first PET. See
Tables 1 and 2 for abbreviations.
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DDNa, and particularly the latter, were the only two
parameters showing a significant variation over time in all
the groups. On the contrary, the classical parameters
of peritoneal transport remained substantially stable
throughout the follow-up. In particular, D/PCreat showed an
increase, especially at the second PET, but over time this
increase was not statistically significant, whereas D/D0
remained stable. This is in agreement with the findings
of previous studies,20,21 indicating that, after an initial
increase of small solute transport, the majority of patients
treated with continuous ambulatory peritoneal dialysis for up
to 3 years experience a stability of peritoneal UF capacity and
of small-solute transport characteristics. The small correla-
tion of the changes between the first and the last PET plotted
against the average of the initial and final value for all
parameters suggest a small influence of the phenomenon of
regression to the mean on the longitudinal changes of
membrane characteristics.22,23
However, the main finding of this study is the different
evolution over time of membrane characteristics in patients
with or without UF failure. First of all, among baseline
parameters, only DDNa independently predicted the devel-
opment of UF failure. Having elevated DDNa at baseline
seems to be protective against the subsequent development of
UF failure; this parameter could therefore be useful to
identify those patients who are at a higher risk of developing
UF failure already at the time of starting PD. In this study, we
could not detect any factor being responsible for the different
baseline DDNa levels observed in the studied PD patients.
However, we did not take into consideration potentially
relevant factors, such as, for example, inflammatory markers,
and at the same time, we did not perform any genetic
evaluation in our patients. Another important finding of this
study is that whereas membrane permeability, expressed as
UF, D/D0, and D/PCreat, remained stable in patients without
UF failure, and increased (UF and D/D0 decreased and
D/PCreat increased) in those developing UF failure, para-
meters related to SNa, as DDNa, decreased in both groups of
patients. It has been suggested by computer simulations that
the reduction of DDNa could be the result of reduced UF
occurring over time.24 However, in our study the reduction
of DDNa always preceded that of peritoneal UF and was
observed even in patients with stable UF. These results
therefore suggest that the first alteration occurring in the
peritoneal membrane characteristics of PD patients might be
a reduction of the osmotic conductance to glucose (LpSsg)
through aquaporin-1 channels, resulting in decreased DDNa,
possibly because of the chronic exposure to peritoneal fluid.25
However, only in a subgroup of patients was this alteration
associated with an increase of peritoneal permeability to
small solutes, and only in these patients UF failure was
observed, therefore suggesting that an increased peritoneal
permeability is a crucial requisite for the development of UF
failure. It has been hypothesized that the increased transport
of small solutes through the peritoneal membrane could be
caused by neoangiogenesis occurring in the peritoneum,
leading to an increase in the effective peritoneal surface
area.26,27 The increased transport of small solutes observed in
patients with UF failure could also at least partly explain why
the reduction of DDNa seemed to occur at a higher rate in
these patients, as it also implies an increased diffusive
transport of sodium from plasma to dialysate, finally
resulting in a more consistent reduction of DDNa.
It is possible to study the SNa of the peritoneal membrane
during a hypertonic dwell through parameters other than
DDNa, such as the ratio of D/P sodium concentration (D/PNa)
at 60 min or the variation of D/PNa between the start and
at 60 min of the test (DD/PNa). Nonetheless, in our opinion
DDNa is the most simple and reliable tool to asses free-
water transport, because D/PNa and DD/PNa are also
dependent on the variation of plasma sodium concentration
over time and on the method used to measure plasma
sodium concentration.28,29
To our knowledge, this is the first report showing the
variation of UF assessed by the 3.86%-PET over a long period
of PD therapy. Furthermore, we showed some interesting
alterations of the function of peritoneal membrane over time,
such as the progressive decrease of the absolute dip of
dialysate sodium concentration, expression of aquaporin-1
function, a stable permeability of the membrane in patients
without UF failure, and an increased permeability of the
membrane in patients with UF failure. Based on the results of
this study, it may be argued that the 3.86%-PET could
substitute the classical 2.27%-PET, as it allows a better
exploration of the function of the peritoneal membrane.
DDNa appears as the first and most suitable marker of
peritoneal membrane function as to UF capacity. If these
results will be confirmed by other studies, DDNa could then
become the main parameter to be considered when studying
early and long-term modifications of the peritoneal mem-
brane. The same parameter could also be very useful when
comparing the effect of different dialysis solutions and
procedures on the preservation of UF and of the transport
characteristics of the peritoneal membrane.
MATERIALS AND METHODS
After the publication of the theory of the ‘three peritoneal
pores’,6,9,30 we began to use the 3.86%-PET to study the peritoneal
UF and the transport characteristics of the peritoneal membrane.
Ninety-five consecutive incident patients starting PD at the A
Manzoni Hospital, Lecco, Italy, were studied from January 1993 to
June 2005, after having given their informed consent. In all these
patients, a 3.86%-PET was performed during the first 12 months
from the start of PD, and then once a year. All patients were treated
with lactate-buffered, conventional dialysis solutions. At the time of
the test, all the patients had been peritonitis-free for at least 4 weeks.
The dwell before the PET (overnight dwell, from 1100 to 0700
hours) was performed using a 2 l PD solution containing a glucose
concentration of 1.36%, with lactate as the buffer. Blood samples
were drawn at the start of the 3.86%-PET, and fresh PD fluid (Dt0’)
samples were taken from the bag at the end of the infusion. After the
complete infusion of a 2 l 3.86% glucose PD solution, 20 ml dialysate
samples were taken at 1, 60, 120, and 240 min (Dt1’, Dt60’, Dt120’,
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Dt240’) after flushing back 30 ml of dialysate. The patients were
instructed to sit up or move about in bed before the drawing of each
dialysate sample; otherwise, they remained recumbent during the
test. After 240 min, the dialysate was collected by gravity for at least
20 min. The volume of the infused fresh PD solution and the
drained dialysate was measured by weighing the bag and then
subtracting the weight of the empty bag; no corrections were made
for differences in the specific weight of the solutions. UF failure was
defined as a net UF of less than 400 ml at the end of a 4-h dwell with
3.86% glucose solution, according to the definition proposed by the
International Society for Peritoneal Dialysis Committee on UF
failure.5 In 13 patients, the 3.86%-PET was repeated 48 h later to
evaluate the coefficient of variation for the net UF volume.
Analytical methods
Plasma and dialysate creatinine, total protein, and glucose
concentrations were analyzed using a Hitachi 717 (Hitachi, Ltd,
Tokyo, Japan); dialysate creatinine concentration was assessed by an
enzymatic method in order to eliminate the effect of the high
dialysate concentration. Total dialysate sodium concentration was
analyzed twice using an IL 943 flame photometer (Instrumentation
Laboratory, Milan, Italy).
Calculations
D/D0 was calculated as the ratio of dialysate glucose concentration
between the end and the start of the PET. D/PCreat was calculated as
the dialysate solute concentration at the end of the PET divided by
creatinine plasma concentration. Plasma water concentrations were
used to calculate D/PCreat.
31 To study SNa, the absolute dip of
dialysate sodium concentration (DDNa) at 60 min of the PET was
used, calculated as follows:
DDNaðmmol=lÞ ¼Na Dialysate ðmmol=lÞ at the start of the PET
 Na Dialysate ðmmol=lÞ at 60min
Both glucose and Na dialysate concentrations at the start of the PET
were measured in fresh PD fluid samples taken from the bag.
Statistical analysis
Results were expressed as mean values71 s.d. or 71 s.e. for
normally distributed data. Median values and inter-quartile range
were given for asymmetrically distributed data. Mean values71 s.d.
of D/PCreat, D/D0, and UF were used to categorize PD patients at
baseline, as reported elsewhere.1 Patients were divided into
cohorts according to the minimal number of PETs performed, so
that changes of the transport characteristics of the peritoneal
membrane were analyzed in the same patients. Repeated
measures analysis of variance was used to evaluate differences of
the same variable between the first and the following PETs within
each cohort. Paired t-test and Wilcoxon’s signed-rank test were
used to evaluate differences of the same variable between the first
and the last PET for data with normal and asymmetrical
distribution, respectively. In those patients who underwent a second
3.86%-PET 48 h after the first, standard deviation of the net UF was
summarized by pooling the individual (SDi) of the N individual
patients (Ni):
Pooled SD ¼p
X
ðSDiÞ2=Ni
The pooled coefficient of variation for the net UF volume was
then obtained from the pooled SD (coefficient of variation¼ pooled
SD/mean).
The Kaplan–Meier curve was used to evaluate the time for the
development of UF failure. The prognostic value for the develop-
ment of UF failure of several variables was analyzed by univariate
and multivariate Cox’s regression analysis. In the first step, all
covariates that were significantly associated with UF failure (Po0.05
at univariate Cox regression analysis) were identified. Then, the
predictive power for UF failure of all significant variables was tested
on multivariate Cox’s models. RRs and their 95% confidence
intervals were calculated with the use of the estimated regression
coefficients and their standard errors in the Cox regression analysis.
Multiple analysis of variance was used to compare changes over time
of the studied parameters between patients with and without UF
failure. To evaluate the phenomenon of regression to the mean,
changes of UF, D/PCreat, D/D0, and DDNa between the first and the
last PET were plotted against the average of the initial and final
values, as suggested by Altman.22 Pearson’s correlation coefficient (r)
was calculated for linear correlation analysis between D/D0, D/PCreat,
DDNa, and UF. When more than one linear correlation was found,
multiple regression was used to explore the dominant relationship.
A P-value of p0.05 was considered as significant. All the
statistical analyses were performed using JMP (SAS Institute Inc.)
for Windows statistical software (release 4.0.0).
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